


Diagnosis & staging

For men diagnosed in England and Wales April 2019 - March 2020:

45,885 men were **diagnosed** with prostate cancer in England and Wales between **1st April 2019 and 31st March 2020**



decrease compared with 52,580 men in 2018-2019*

*this may be explained by the diagnosis of two high-profile celebrities during this previous reporting period, which was publicised by the media

55% of men were **70 years or older**




13% of men presented with **metastatic** disease

Treatment outcomes

For men undergoing surgery in England and Wales between April 2019 - March 2020:

13% of men were **readmitted** within 3 months following surgery



This is **stable** compared with 2018-2019

For men undergoing radical treatment in 2018:

7% experienced at least one **genitourinary** complication requiring a procedural/surgical intervention within two years after **radical prostatectomy**

11% experienced at least one **gastrointestinal** complication requiring a procedural/surgical intervention within two years after **radical radiotherapy**

Decrease compared to 9% in 2017

Stable compared to 11% in 2017

Treatment allocation

For men diagnosed in Wales April 2019 - March 2020:

Low-risk, localised disease

High-risk/locally advanced disease


10% of men had radical treatments and were **potentially 'over-treated'** 16% in 2018-2019

40% of men did not have radical treatments and were **potentially 'under-treated'** - 34% in 2018-2019



Impact on Diagnosis


Number of patients newly diagnosed with prostate cancer in 2020 (compared to same period in 2019)



* There was a 54% reduction in the number of men diagnosed between April - June 2020 compared with same period in 2019


Impact on Radical treatment received

Number of patients undergoing radical prostatectomy in 2020 (compared to same period in 2019)



* There was a 48% reduction in the number of men undergoing prostatectomy between April - June 2020 compared with same period in 2019

Number of patients undergoing radical radiotherapy in 2020 (compared to same period in 2019)



* There was a 45% reduction in the number of men undergoing radiotherapy between April - June 2020 compared with same period in 2019

Impact on systemic therapy

Rapid and marked **fall of Docetaxel use** from April 2020 in metastatic hormone-sensitive prostate cancer. Conversely, rapid and marked **increased use of Enzalutamide**

